Agree. Whilst we wait for ODD, funding, enrolment and commencement into the critical adaptive phase 2 and 3 trials, the ongoing results of these 12 patients while they continue on treatment will be telling, even if a small group.
Ann: Final Ethics Approval for Open-Label MND Extension Study, page-7
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $141.2K | 801.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 537419 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 140000 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |